Biodexa reports 100 patients enrolled in Serenta Phase 3 trial
Biodexa announced that 100 patients have enrolled in its registrational Phase 3 trial of Serenta in FAP.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.